Nebicard (Nebivolol Hydrochloride)

Nebivolol is a selective β1‑adrenergic antagonist indicated for conditions affecting the cardiovascular system.

• Hypertension: lowers elevated systolic and diastolic blood pressure to reduce cardiovascular risk.
• Heart Failure (reduced ejection fraction): improves cardiac output and symptoms in patients with chronic heart failure.
• Elderly patients with hypertension: provides effective blood pressure control with a favorable tolerability profile.

• Nebivolol Hydrochloride selectively blocks β1‑adrenergic receptors, reducing heart rate and myocardial contractility, which lowers cardiac output and blood pressure. In addition, it stimulates endothelial nitric oxide release, causing vasodilation and further contributing to its antihypertensive effect without significant β2 blockade.

Nebivolol may cause a range of adverse reactions, most of which are mild and dose‑related.

Common Side Effects

• Headache: mild to moderate pain often occurring early in therapy.
• Dizziness: sensation of light‑headedness, especially when standing.
• Fatigue: generalized tiredness or reduced energy.
• Nausea: occasional stomach upset or queasiness.
• Bradycardia: slower than normal heart rate.
• Peripheral edema: mild swelling of ankles or feet.

Serious or Rare Side Effects

• Severe bradycardia: markedly low heart rate requiring medical attention.
• Symptomatic hypotension: significant drop in blood pressure causing faintness.
• Heart block: conduction abnormalities that may need intervention.
• Bronchospasm: airway constriction, particularly in patients with asthma.
• Allergic reactions: rash, itching, or swelling of face and throat.
• Hepatic dysfunction: abnormal liver enzymes indicating liver stress.

Before initiating Nebicard, clinicians should evaluate patient-specific factors and monitor for potential risks.

• Cardiovascular assessment: review baseline heart rate and blood pressure.
• Hepatic impairment: adjust use in patients with liver disease.
• Asthma or COPD: use with caution due to possible bronchospasm.
• Diabetes monitoring: observe for changes in blood glucose control.
• Abrupt discontinuation: taper gradually to avoid rebound hypertension.
• Store below 25°C: keep in the original pack, protect from moisture.

Nebivolol can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Other beta‑blockers: additive negative chronotropic effects.
• Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): increased risk of bradycardia and AV block.
• Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may raise nebivolol plasma levels.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance hypotensive effect.

• ACE inhibitors or ARBs: combined use can lead to excessive blood pressure reduction.
• NSAIDs: may blunt antihypertensive response.
• Antiarrhythmic agents (e.g., amiodarone): potential for conduction disturbances.